Cytokinetics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	88.04	18.47	7.53	94.59	70.43
Revenue Growth (YoY)	376.56%	145.34%	-92.04%	34.30%	26.15%
Cost of Revenue	416.03	339.41	330.12	240.81	159.94
Gross Profit	-327.99	-320.93	-322.59	-146.23	-89.51
Selling, General & Admin	284.27	215.31	173.61	177.98	96.8
Research & Development	416.03	339.41	330.12	240.81	159.94
Total Operating Expenses	700.3	554.72	503.74	418.79	256.74
Operating Income	-612.26	-536.25	-496.21	-324.2	-186.31
Interest Income	48.42	51.53	27.63	11.34	0.33
Interest Expense	-103.87	-86.51	-57.67	-76.1	-29.33
Other Non-Operating Income (Expense)	-117.25	-18.3	-	-	-
Total Non-Operating Income (Expense)	-172.7	-53.28	-30.04	-64.75	-29
Pretax Income	-784.96	-589.53	-526.24	-388.96	-215.31
Net Income	-784.96	-589.53	-526.24	-388.96	-215.31
Net Income to Common	-784.96	-589.53	-526.24	-388.96	-215.31
Shares Outstanding (Basic)	120	112	97	90	77
Shares Outstanding (Diluted)	120	112	97	90	77
Shares Change (YoY)	7.26%	16.01%	7.46%	16.83%	19.16%
EPS (Basic)	-6.54	-5.26	-5.45	-4.33	-2.80
EPS (Diluted)	-6.54	-5.26	-5.45	-4.33	-2.80
Free Cash Flow	-534.82	-399.8	-415.75	-310.85	-191.39
Free Cash Flow Per Share	-4.45	-3.57	-4.31	-3.46	-2.49
Gross Margin	-372.55%	-1737.22%	-4284.10%	-154.59%	-127.09%
Operating Margin	-695.44%	-2902.72%	-6589.71%	-342.75%	-264.54%
Profit Margin	-891.60%	-3191.11%	-6988.63%	-411.21%	-305.72%
FCF Margin	-607.48%	-2164.10%	-5521.24%	-328.64%	-271.76%
EBITDA	-602.13	-526.72	-484.31	-318.39	-184.04
EBITDA Margin	-683.94%	-2851.13%	-6431.78%	-336.61%	-261.31%
EBIT	-612.26	-536.25	-496.21	-324.2	-186.31
EBIT Margin	-695.44%	-2902.72%	-6589.71%	-342.75%	-264.54%

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q